NCT00697697View on ClinicalTrials.gov

A Study of 2 Doses of MAP0010 in Asthmatic Children

PHASE3TerminatedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

December 31, 2009

Conditions
Asthma
Interventions
DRUG

0.135mg MAP0010

0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks

DRUG

0.25mg MAP0010

0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY